Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
5-day change
1st Jan Change
1.11
USD
-9.76%
-8.26%
-16.54%
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to the Co-Diagnost...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Co-Diagnostics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09
Co-Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 09
CI
Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event
Apr. 12
CI
Co-Diagnostics, Inc. Appoints Executive Appointments
Apr. 04
CI
Co-Diagnostics, Inc. Appoints Richard Abbott as President
Mar. 15
CI
Transcript : Co-Diagnostics, Inc., Q4 2023 Earnings Call, Mar 14, 2024
Mar. 14
Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.
Mar. 14
CI
Co-Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 14
CI
Co-Diagnostics Gets Approval From India's Central Drugs Standard Control Organization For Manufacturing, Sale of Influenza Multiplex Test
Mar. 07
MT
Co-Diagnostics Submits PCR COVID-19 Test and PCR Pro Instrument for FDA Review
Dec. 27
MT
Co-Diagnostics Shares Rise 21% After Submitting FDA Application For Covid-19 Test Platform
Dec. 27
DJ
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro
Dec. 27
CI
HC Wainwright Adjusts Price Target on Co-Diagnostics to $3 From $2, Maintains Neutral Rating
Nov. 13
MT
Transcript : Co-Diagnostics, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Nov. 09
Earnings Flash (CODX) CO-DIAGNOSTICS Reports Q3 Revenue $2.5M
Nov. 09
MT
Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.
Nov. 09
CI
Co-Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 09
CI
Co-Diagnostics, Inc.(NasdaqCM:CODX) dropped from S&P Global BMI Index
23-09-18
CI
Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer
23-08-29
CI
HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $3, Keeps Neutral Rating
23-08-14
MT
Transcript : Co-Diagnostics, Inc., Q2 2023 Earnings Call, Aug 10, 2023
23-08-10
Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.
23-08-10
CI
Co-Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-10
CI
Earnings Flash (CODX) CO-DIAGNOSTICS Posts Q2 Revenue $0.2M
23-08-10
MT
Co-Diagnostics Wins Gates Foundation Grants for Tuberculosis, HPV Tests
23-07-18
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Companyâs technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the userâs mobile device.
More about the company
Last Close Price
1.11
USD
Average target price
2.5
USD
Spread / Average Target
+125.23%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1